Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: EPI-743; Vincerenone

Latest Information Update: 08 Nov 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Edison Pharmaceuticals
  • Developer BioElectron Technology; Sumitomo Dainippon Pharma; University of Florida; Yale University
  • Class Alkadienes; Benzoquinones; Cyclohexenes; Small molecules
  • Mechanism of Action Antioxidants; NQO1 modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Mitochondrial disorders; Friedreich's ataxia; Leigh disease
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Leigh disease
  • Phase II Friedreich's ataxia; Methylmalonic acidaemia; Mitochondrial disorders; Noise-induced hearing loss; Parkinson's disease; Rett syndrome
  • No development reported Gilles de la Tourette's syndrome

Most Recent Events

  • 01 Oct 2019 PTC Therapeutics acquires vatiquinone from BioElectron Technology
  • 01 Aug 2018 Edison Pharmaceuticals is now called BioElectron Technology
  • 24 Jun 2018 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top